Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

The present invention generally relates to systems and methods to create stable emulsions with low rates of exchange of molecules between microdroplets.

The present invention is directed to methods for detecting a melanoma, methods for determining whether a melanoma is stable or progressive, methods for evaluating the extent of surgery resection in a subject having a melanoma, and methods for determining a response by a subject having a melanoma to a therapy.

Disclosed are a method and a device for constructing an antibody complementarity determining region (CDR) library. Also disclosed are a method, a device and a computer program product for determining the occurrence frequency of member sequences of an antibody CDR library, by means of which an antibody CDR library with a specific amino acid distribution at one or more positions can be obtained.

A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies.

Provided herein are systems, devices and methods for performing multianalyte detection in a biological sample, such as a human blood sample. Multiwell plates useful for performing multianalyte detection are also provided. The systems, devices and methods provided herein relate to the field of direct-to-consumer diagnostics (DTC diagnostics) and are useful, e.g., for facilitating consumer access to consumer healthcare and consumer wellness information. Other uses of the systems, devices and methods provided herein relate to the fields of medical research and drug discovery.

The invention relates to one or more aptamers isolated against the SARS-CoV-2 spike protein and methods of using the same. Certain embodiments of the invention relate to methods of detecting the presence, absence or amount of SARS-CoV-2 in a sample using the one or more aptamers described herein. In certain embodiments, the invention relates to one or more aptamers that are capable of specifically binding to SARS-CoV-2 proteins, including aptamers that are capable of specifically binding to the S1 subunit (including the receptor binding domain (RBD)) and/or the S2 subunit within their native conformation as part of the SARS-CoV-2 spike protein in its trimeric form or as separate monomers.

The present invention provides a novel IGFR-like receptor and antagonists and agonists for targeting said receptor. Said antagonists and agonists are envisaged for use as a medicament, and in particular for treatment of diabetes.

The present invention provides a novel IGFR-like receptor and antagonists and agonists for targeting said receptor. Said antagonists and agonists are envisaged for use as a medicament, and in particular for treatment of diabetes.

Kits and methods for the detection and enrichment of RNA viruses of the family Coronaviridae. The detection method comprises the steps of (a) coupling a binding agent that specifically recognizes and binds to a virus component to a carrier material, (b) incubating the carrier material with the thereon coupled binding agent with a virus-containing sample, (c) staining the viruses immobilised on the carrier material with a staining agent, and (d) detecting stained virus particles via a physical, chemical or biological detection means. The methods may be suitable for the rapid and efficient detection of coronaviruses, such as SARS-CoV-2. With the methods and kits, it is possible to perform rapid high-throughput tests in a large population. At the same time, the enrichment procedure makes it possible to enrich viral samples, e.g. from a throat swab of a patient, for use in a subsequent PCR.